Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Pharmacology of intrathecal VP-16-213 in dogs.

Savaraj N, Feun LG, Lu K, Gray K, Wang C, Loo TL.

J Neurooncol. 1992 Jul;13(3):211-5.

PMID:
1517797
2.

Pharmacokinetics of potential anti-AIDS agents thiofoscarnet and foscarnet in the cat.

Straw JA, Loo TL, de Vera CC, Nelson PD, Tompkins WA, Bai SA.

J Acquir Immune Defic Syndr (1988). 1992;5(9):936-42.

PMID:
1387417
3.

Pharmacokinetics of homoharringtonine in dogs.

Lu K, Savaraj N, Feun LG, Guo ZG, Umsawasdi T, Loo TL.

Cancer Chemother Pharmacol. 1988;21(2):139-42.

PMID:
3349562
4.

Central nervous system (CNS) penetration of homoharringtonine (HHT).

Savaraj N, Feun LG, Lu K, Leavens M, Moser R, Fields WS, Loo TL.

J Neurooncol. 1987;5(1):77-81.

PMID:
3598625
5.
6.

Clinical pharmacology of homoharringtonine.

Savaraj N, Lu K, Dimery I, Feun LG, Burgess M, Keating M, Loo TL.

Cancer Treat Rep. 1986 Dec;70(12):1403-7.

PMID:
3791253
7.

Clinical pharmacokinetics of 9, 10-anthracenedicarboxaldehyde-bis [(4,5-dihydro-1 H-imidazol-2-yl)hydrazone]dihydrochloride.

Lu K, Savaraj N, Yap BS, Feun LG, Umsawasdi T, Loo TL.

Cancer Chemother Pharmacol. 1986;16(2):156-9.

PMID:
3948302
8.

Clinical pharmacology of intracarotid etoposide.

Savaraj N, Feun LG, Lu K, Wallace S, Fields WS, Loo TL.

Cancer Chemother Pharmacol. 1986;16(3):292-4.

PMID:
3698170
9.

Clinical pharmacology of 4-demethoxydaunorubicin (DMDR).

Lu K, Savaraj N, Kavanagh J, Feun LG, Burgess M, Bodey GP, Loo TL.

Cancer Chemother Pharmacol. 1986;17(2):143-8.

PMID:
3459594
10.

Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study.

Chiuten DF, Miller A, Valdivieso M, Loo TL, Bedikian A, Bodey GP, Benvenuto JA, Freireich EJ.

Am J Clin Oncol. 1985 Aug;8(4):332-5.

PMID:
4083263
12.

Inhibition of ribonucleotide reductase by caracemide.

Moore EC, Loo TL.

Cancer Treat Rep. 1984 Oct;68(10):1293-4.

PMID:
6395952
13.

Alkylation of DNA by the new anticancer agent 3,6-diaziridinyl-2,5-bis(carboethoxyamino)-1,4-benzoquinone (AZQ).

King CL, Wong SK, Loo TL.

Eur J Cancer Clin Oncol. 1984 Feb;20(2):261-4.

PMID:
6538490
14.
15.

Human tissue distribution of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (NSC 141549, AMSA).

Stewart DJ, Zhengang G, Lu K, Savaraj N, Feun LG, Luna M, Benjamin RS, Keating MJ, Loo TL.

Cancer Chemother Pharmacol. 1984;12(2):116-9.

PMID:
6583026
16.

Effect of thymidine on the toxicity and antitumor activity of cis-diamminedichloroplatinum (II).

Grossie VB Jr, Valdivieso M, Drewinko B, Loo TL.

Cancer Chemother Pharmacol. 1984;13(1):27-30.

PMID:
6539657
17.

Central nervous system pharmacology of Baker's antifolate (NSC139105) in man.

Stewart DJ, Leavens M, Lu K, Wang YM, Benjamin RS, Ho DH, Yap HY, Loo TL.

J Neurooncol. 1984;2(3):187-93.

PMID:
6094740
18.

Human pharmacokinetics of a new acridine derivative, 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992).

Hall SW, Friedman J, Legha SS, Benjamin RS, Gutterman JU, Loo TL.

Cancer Res. 1983 Jul;43(7):3422-6.

19.
20.

Immune restoration and/or augmentation of local graft versus host reaction by traditional Chinese medicinal herbs.

Sun Y, Hersh EM, Talpaz M, Lee SL, Wong W, Loo TL, Mavligit GM.

Cancer. 1983 Jul 1;52(1):70-3.

PMID:
6336578
21.

Pharmacological and biochemical interactions of N-(phosphonacetyl)-L-aspartate and 5-fluorouracil in beagles.

Miller AA, Moore EC, Hurlbert RB, Benvenuto JA, Loo TL.

Cancer Res. 1983 Jun;43(6):2565-70.

22.

Clinical pharmacology of 2,5'-diaziridinyl-3,6-biscarboethoxyamino-1,4-benzoquinone (AZQ).

Lu K, Savaraj N, Yap BS, Bedikian AY, Feun L, Benjamin RS, Loo TL.

Eur J Cancer Clin Oncol. 1983 May;19(5):603-6.

PMID:
6683631
23.

Inhibition of hepatic drug metabolism in the rat after Corynebacterium parvum treatment.

Farquhar D, Benvenuto JA, Kuttesch N, Loo TL.

Biochem Pharmacol. 1983 Apr 1;32(7):1275-80.

PMID:
6847717
24.

Negative-ion chemical-ionization mass spectrometry of aclarubicin analogs and characterization of two metabolites in man.

Smith RG, Miller AA, Benvenuto JA, Valdivieso M, Loo TL.

Cancer Treat Rep. 1983 Apr;67(4):351-4.

PMID:
6573957
25.

Clinical pharmacokinetics of vinblastine by continuous intravenous infusion.

Lu K, Yap HY, Loo TL.

Cancer Res. 1983 Mar;43(3):1405-8.

26.

Effect of nutritional status on the hepatobiliary excretion of methotrexate in the rat.

Grossie VB Jr, Loo TL.

Cancer Treat Rep. 1983 Mar;67(3):253-7.

PMID:
6403239
27.

Clinical pharmacokinetics of 5-methyltetrahydrohomofolate.

Loo TL, Jiushi L, Lu K, Savaraj N.

Cancer Res. 1983 Feb;43(2):921-4.

PMID:
6848202
28.

Clinical pharmacology of intraarterial cis-diamminedichloroplatinum(II).

Stewart DJ, Benjamin RS, Zimmerman S, Caprioli RM, Wallace S, Chuang V, Calvo D 3rd, Samuels M, Bonura J, Loo TL.

Cancer Res. 1983 Feb;43(2):917-20.

PMID:
6681533
29.

Determination of the biological response modifier MVE-2 (AD-022) in biological fluids by high-performance liquid chromatography.

Rosenblum MG, Hersh EM, Loo TL.

J Chromatogr. 1983 Jan 14;272(1):200-4. No abstract available.

PMID:
6841541
30.

Tumor penetration of AMSA in man.

Guo ZG, Savaraj N, Feun LG, Lu K, Stewart DJ, Luna M, Benjamin RS, Loo TL.

Cancer Invest. 1983;1(6):475-8.

PMID:
6689404
31.

The pharmacologic fate of 2,5-diaziridinyl-3,6-bis(carboethoxyamino) 1,4-benzoquinone (AZQ NSC-182986) by intracarotid or intravenous administration in beagles.

Feun LG, Savaraj N, Lu K, Guo Z, Raulston LG, Benjamin RS, Fields WS, Loo TL.

J Neurooncol. 1983;1(3):219-24.

PMID:
6678971
32.

Concentration of vinblastine in human intracerebral tumor and other tissues.

Stewart DJ, Lu K, Benjamin RS, Leavens ME, Luna M, Yap HY, Loo TL.

J Neurooncol. 1983;1(2):139-44.

PMID:
6678966
33.

Intracerebral penetration and tissue distribution of 2,5-diaziridinyl 3,6-bis(carboethoxyamino) 1,4-benzoquinone (AZQ, NSC-182986).

Savaraj N, Lu K, Feun LG, Leavens ME, Stewart D, Burgess MA, Benjamin RS, Loo TL.

J Neurooncol. 1983;1(1):15-9.

PMID:
6678302
34.
35.

Human central nervous system pharmacology of pentamethylmelamine and its metabolites.

Stewart DJ, Benvenuto JA, Leavens M, Smith RG, Cabanillas F, Benjamin RS, Loo TL.

J Neurooncol. 1983;1(4):357-64.

PMID:
6432969
36.

Human tissue distribution of platinum after cis-diamminedichloroplatinum.

Stewart DJ, Benjamin RS, Luna M, Feun L, Caprioli R, Seifert W, Loo TL.

Cancer Chemother Pharmacol. 1982 Dec;10(1):51-4.

PMID:
6891626
37.

Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate.

Moore EC, Friedman J, Valdivieso M, Plunkett W, Marti JR, Russ J, Loo TL.

Biochem Pharmacol. 1982 Oct 15;31(20):3317-21.

PMID:
7150358
38.

Combination chemotherapy with cyclophosphamide and ftorafur against advanced L1210 murine leukemia.

Grossie VB Jr, Rosenblum MG, Loo TL.

Cancer Treat Rep. 1982 Aug;66(8):1631-4.

PMID:
6809329
39.

Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors.

Stewart DJ, Leavens M, Maor M, Feun L, Luna M, Bonura J, Caprioli R, Loo TL, Benjamin RS.

Cancer Res. 1982 Jun;42(6):2474-9. No abstract available.

40.
41.

Clinical kinetics of 1, 4-dihydroxy-5,8-bis [(2-[(2-hydroxyethyl) amino] ethyl] amino ]-9, 10-anthracenedione.

Savaraj N, Lu K, Valdivieso M, Burgess M, Umsawasdi T, Benjamin RS, Loo TL.

Clin Pharmacol Ther. 1982 Mar;31(3):312-6.

PMID:
7060314
42.

Pharmacokinetics and metabolism of beta-2'-deoxythioguanosine and 6-thioguanine in man.

Lu K, Benvenuto JA, Bodey GP, Gottlieb JA, Rosenblum MG, Loo TL.

Cancer Chemother Pharmacol. 1982;8(1):119-23.

PMID:
7094197
43.

Pharmacology of mitoxantrone in cancer patients.

Savaraj N, Lu K, Manuel V, Loo TL.

Cancer Chemother Pharmacol. 1982;8(1):113-7.

PMID:
7094196
44.

Effect of malnutrition on methotrexate toxicity and tissue levels of dihydrofolate reductase in the rat.

Grossie VB Jr, Ho DH, Loo TL.

Cancer Treat Rep. 1982 Jan;66(1):85-9.

PMID:
7053272
45.

Stability and compatibility of antitumor agents in glass and plastic containers.

Benvenuto JA, Anderson RW, Kerkof K, Smith RG, Loo TL.

Am J Hosp Pharm. 1981 Dec;38(12):1914-8.

PMID:
7325172
46.

Effect of thymidine on the toxicity and antitumor activity of ftorafur.

Grossie VB Jr, Loo TL.

Cancer Treat Rep. 1981 Nov-Dec;65(11-12):1087-91.

PMID:
6794908
47.

Identification of the metabolites of an antitumor tricyclic nucleoside (NSC-154020).

Schweinsberg PD, Smith RG, Loo TL.

Biochem Pharmacol. 1981 Sep 15;30(18):2521-6. No abstract available.

PMID:
7306204
48.

Actions of 3-deazaguanine and 3-deazaguanosine on variant lines of Chinese hamster ovary cells.

Saunders PP, Chao LY, Loo TL, Robins RK.

Biochem Pharmacol. 1981 Aug 15;30(16):2374-6. No abstract available.

PMID:
7295349
49.

Analysis for nitrosourea antitumor agents by gas chromatography--mass spectrometry.

Smith RG, Blackstock SC, Cheung LK, Loo TL.

Anal Chem. 1981 Jul;53(8):1205-8. No abstract available.

PMID:
7270897
50.

Pharmacokinetics of [14C]methylglyoxal-bis-guanylhydrazone) in patients with leukemia.

Rosenblum MG, Keating MJ, Yap BS, Loo TL.

Cancer Res. 1981 May;41(5):1748-50.

Supplemental Content

Support Center